Experimental women’s cancer drug boosts survival rates in notable study
A new drug is showing promise in tackling treatment-resistant ovarian cancer.
Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve overall survival and progression of the disease when matched with a chemotherapy drug called nab-paclitaxel.
The ROSELLA trial, conducted in collaboration with The GOG Foundation, analyzed 381 patients around the world, including the U.S., Europe, South Korea, Brazil, Argentina, Canada and Australia, according to a press release.
AI DETECTS OVARIAN CANCER BETTER THAN HUMAN EXPERTS IN NEW STUDY
The large, randomized phase 3 study revealed a 30% reduction in risk of disease progression in patients with platinum-resistant ovarian cancer, compared to those just treated with nab-paclitaxel. (Some types of chemotherapy contain the element platinum.)
The researchers also noted «significant improvement» in overall survival with this combination of drugs.
Relacorilant, which is administered as an oral..